Clinical Trials
6 trialsNCT06494189 2025-12-29
Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma
West China Hospital
Phase 1 Completed
NCT06804850 2025-11-19
Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC
West China Hospital
Phase 2 Withdrawn
NCT05517330 2025-07-31
neoCHANCE-1
West China Hospital
Phase 2 Completed
NCT05516589 2025-05-22
neoCHANCE-2
West China Hospital
Phase 2 Completed
NCT03695510 2022-04-21
ALPHA
National Taiwan University Hospital
Phase 2 Completed
NCT01721525 2017-10-25
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed